RxDoctor Payments Data

Aruna Gowda, MD

Hematology & Oncology · Newark, OHNPI 1407070576

Payments from drug & device makers

$6,052in general payments, 2019–2025

Across 36 payments — averaging $168.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$5K
  • AstraZeneca$422
  • Novocure GmbH$200
  • GSK$100
  • Amgen$99
  • Exelixis Inc.$70
  • plus $88 from 4 others

What the payments were for

  • Consulting fees$10010%
  • Speaking & faculty fees$60061%
  • Food & beverage$151%
  • Education$26427%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,052 in reported general payments places this provider in the 50th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$58,985
Medicare patients
305
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax37$485,299
NubeqaDarolutamide22$268,504
ImbruvicaIbrutinib13$212,772
AlecensaAlectinib Hcl12$210,953
VerzenioAbemaciclib14$178,231
Lenalidomide11$98,288
Abiraterone Acetate20$40,846
XareltoRivaroxaban50$35,616
EliquisApixaban43$26,358
Imatinib Mesylate25$18,948
Anastrozole173$2,723
Oxycodone Hcl47$1,208
Potassium Chloride18$1,067
Ondansetron Hcl141$942
Hydroxyurea38$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$26,35843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Newark

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →